JP2010530431A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010530431A5 JP2010530431A5 JP2010513266A JP2010513266A JP2010530431A5 JP 2010530431 A5 JP2010530431 A5 JP 2010530431A5 JP 2010513266 A JP2010513266 A JP 2010513266A JP 2010513266 A JP2010513266 A JP 2010513266A JP 2010530431 A5 JP2010530431 A5 JP 2010530431A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- group
- structural formula
- nitrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 102000011990 Sirtuin Human genes 0.000 claims 4
- 108050002485 Sirtuin Proteins 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229910052760 oxygen Chemical group 0.000 claims 2
- 239000001301 oxygen Chemical group 0.000 claims 2
- -1 1,2,4-triazolylmethyl group Chemical group 0.000 claims 1
- 101000654472 Homo sapiens NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 102100030710 NAD-dependent protein deacetylase sirtuin-3, mitochondrial Human genes 0.000 claims 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 1
- 108091005770 SIRT3 Proteins 0.000 claims 1
- 102000000344 Sirtuin 1 Human genes 0.000 claims 1
- 108010041191 Sirtuin 1 Proteins 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000002921 anti-spasmodic effect Effects 0.000 claims 1
- 230000006196 deacetylation Effects 0.000 claims 1
- 238000003381 deacetylation reaction Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 102000056482 human SIRT1 Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 239000002510 pyrogen Substances 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000024883 vasodilation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93663307P | 2007-06-20 | 2007-06-20 | |
| US60/936,633 | 2007-06-20 | ||
| PCT/US2008/007771 WO2008156866A1 (en) | 2007-06-20 | 2008-06-20 | Sirtuin modulating imidazothiazole compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010530431A JP2010530431A (ja) | 2010-09-09 |
| JP2010530431A5 true JP2010530431A5 (OSRAM) | 2011-08-04 |
| JP5281081B2 JP5281081B2 (ja) | 2013-09-04 |
Family
ID=39810276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010513266A Expired - Fee Related JP5281081B2 (ja) | 2007-06-20 | 2008-06-20 | サーチュイン調節性イミダゾチアゾール化合物 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7829556B2 (OSRAM) |
| EP (1) | EP2167510B1 (OSRAM) |
| JP (1) | JP5281081B2 (OSRAM) |
| KR (1) | KR101525268B1 (OSRAM) |
| CN (1) | CN101874031B (OSRAM) |
| AR (1) | AR067106A1 (OSRAM) |
| AU (1) | AU2008266746B2 (OSRAM) |
| BR (1) | BRPI0813653A2 (OSRAM) |
| CA (1) | CA2692099C (OSRAM) |
| CL (1) | CL2008001821A1 (OSRAM) |
| CO (1) | CO6261382A2 (OSRAM) |
| CR (1) | CR11231A (OSRAM) |
| DO (1) | DOP2009000283A (OSRAM) |
| EA (1) | EA018182B1 (OSRAM) |
| ES (1) | ES2534544T3 (OSRAM) |
| IL (1) | IL202729A (OSRAM) |
| MA (1) | MA31568B1 (OSRAM) |
| MX (1) | MX2009013976A (OSRAM) |
| MY (1) | MY149316A (OSRAM) |
| NZ (1) | NZ581989A (OSRAM) |
| PE (1) | PE20090423A1 (OSRAM) |
| TW (1) | TW200918542A (OSRAM) |
| UA (1) | UA104127C2 (OSRAM) |
| UY (1) | UY31170A1 (OSRAM) |
| WO (1) | WO2008156866A1 (OSRAM) |
| ZA (1) | ZA200908882B (OSRAM) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
| US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
| JP2008535790A (ja) * | 2005-03-03 | 2008-09-04 | サートリス ファーマシューティカルズ， インコーポレイテッド | サーチュインモジュレーターであるｎ−フェニルベンズアミド誘導体 |
| AU2006278504B2 (en) | 2005-08-04 | 2013-01-17 | Sirtris Pharmaceuticals, Inc. | Imidazopyridine derivatives as sirtuin modulating agents |
| US20070077310A1 (en) * | 2005-10-03 | 2007-04-05 | University Of Tennessee Research Foundation | Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species |
| TW200918542A (en) * | 2007-06-20 | 2009-05-01 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| CL2008001822A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
| WO2009029614A1 (en) * | 2007-08-27 | 2009-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
| US20120156134A1 (en) | 2007-12-20 | 2012-06-21 | Shayne Squires | Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease |
| WO2009099643A1 (en) * | 2008-02-07 | 2009-08-13 | The J. David Gladstone Institutes | Use of sirt1 activators or inhibitors to modulate an immune response |
| WO2009146030A1 (en) | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
| US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
| BRPI0912356A2 (pt) * | 2008-05-01 | 2015-10-06 | Sirtris Pharmaceuticals Inc | compostos moduladores de sirtuína, composição farmacêutica compreendendo os mesmos e seu uso |
| CA2729128C (en) * | 2008-07-03 | 2016-05-31 | Sirtris Pharmaceuticals, Inc. | Benzimidazoles and related analogs as sirtuin modulators |
| WO2010037129A1 (en) | 2008-09-29 | 2010-04-01 | Sirtris Pharmaceuticals Inc. | Quinazolinone, quinolone and related analogs as sirtuin modulators |
| US8412338B2 (en) | 2008-11-18 | 2013-04-02 | Setpoint Medical Corporation | Devices and methods for optimizing electrode placement for anti-inflamatory stimulation |
| EP2367563A4 (en) | 2008-12-08 | 2012-12-19 | Univ Northwestern | PROCESS FOR HSF-1 MODULATION |
| CN102388054B (zh) | 2008-12-19 | 2015-03-04 | 西特里斯药业公司 | 噻唑并吡啶沉默调节蛋白调节剂的化合物 |
| US8996116B2 (en) * | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
| US20110054569A1 (en) * | 2009-09-01 | 2011-03-03 | Zitnik Ralph J | Prescription pad for treatment of inflammatory disorders |
| US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| CN102573986B (zh) | 2009-06-09 | 2016-01-20 | 赛博恩特医疗器械公司 | 用于无导线刺激器的具有袋部的神经封套 |
| CA2779303A1 (en) | 2009-10-29 | 2011-05-19 | Sirtris Pharmaceuticals, Inc. | Bicyclic pyridines and analogs as sirtuin modulators |
| DK2496594T3 (en) * | 2009-11-06 | 2018-03-05 | The J David Gladstone Inst | METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS |
| WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
| US9833621B2 (en) * | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
| EP2515996B1 (en) | 2009-12-23 | 2019-09-18 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
| EP2993236A1 (en) | 2010-04-15 | 2016-03-09 | Glaxosmithkline LLC | Sirtuin activators and activation assays |
| US9089588B2 (en) | 2010-05-03 | 2015-07-28 | Curna, Inc. | Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT) |
| WO2011143317A2 (en) * | 2010-05-11 | 2011-11-17 | President And Fellows Of Harvard College | Methods for the regulation of cellular metabolism through the modulation of sirt3 activity |
| US20130338178A1 (en) | 2011-02-02 | 2013-12-19 | The Trustees Of Princeton University | Sirtuin modulators as inhibitors of cytomegalovirus |
| US12172017B2 (en) | 2011-05-09 | 2024-12-24 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| EP2707094B1 (en) | 2011-05-09 | 2016-02-03 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| EP3466418A1 (en) | 2011-07-15 | 2019-04-10 | NuSirt Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| BR112014014529A2 (pt) | 2011-12-13 | 2019-09-24 | Buck Inst For Res On Aging | métodos para melhorar terapias médicas |
| US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
| US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
| US20150064137A1 (en) | 2012-04-17 | 2015-03-05 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| CN108452311A (zh) | 2012-11-13 | 2018-08-28 | 纽斯尔特科学公司 | 用于增强能量代谢的组合物和方法 |
| WO2014152016A1 (en) | 2013-03-15 | 2014-09-25 | Nusirt Sciences, Inc. | Leucine and nicotinic acid reduces lipid levels |
| WO2015002892A1 (en) * | 2013-07-01 | 2015-01-08 | Meier Joshua Abraham | Methods of treating diseases by modulating mitochondrial dna deletions |
| MX2016011063A (es) | 2014-02-27 | 2016-11-30 | Nusirt Sciences Inc | Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica. |
| MX2016015997A (es) | 2014-06-02 | 2017-04-05 | Glaxosmithkline Intellectual Property (No 2) Ltd | Preparacion y uso de beta-d-nicotinamida ribosido cristalina. |
| US10485814B2 (en) | 2014-06-06 | 2019-11-26 | Glaxosmithkline Intellectual Property (No. 2) Limited | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof |
| US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
| US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
| KR101839688B1 (ko) | 2015-08-21 | 2018-03-19 | 중앙대학교 산학협력단 | 이미다조티아졸 유도체 또는 이의 약학적으로 허용 가능한 염 및 이의 의약적 용도 |
| US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
| WO2017123161A1 (en) * | 2016-01-15 | 2017-07-20 | Agency For Science, Technology And Research | Inhibition of intracellular growth of mycobacterium species and its applications |
| WO2017127758A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
| WO2017127756A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Control of vagal stimulation |
| US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
| US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
| JP6727317B2 (ja) | 2016-02-22 | 2020-07-22 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 肝臓の再生を向上させるための方法 |
| WO2019036470A1 (en) | 2017-08-14 | 2019-02-21 | Setpoint Medical Corporation | TESTING TEST FOR STIMULATION OF NERVE WAVE |
| US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
| CN109700790A (zh) * | 2018-12-28 | 2019-05-03 | 中南大学湘雅医院 | 一种靶向AQP3的抗皮肤衰老药物Butein |
| AU2020272128B9 (en) | 2019-04-12 | 2025-11-20 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| CN111000854B (zh) * | 2019-12-30 | 2023-06-09 | 昆药集团股份有限公司 | 曲札茋苷在制备治疗和/或预防非酒精性脂肪肝病产品中的应用 |
| IL298193B2 (en) | 2020-05-21 | 2024-01-01 | Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
| US12444497B2 (en) | 2021-05-17 | 2025-10-14 | Setpoint Medical Corporation | Neurostimulation parameter authentication and expiration system for neurostimulation |
| CN119698275A (zh) * | 2022-06-17 | 2025-03-25 | 科达根生物科学股份有限公司 | 包括沉默信息调节蛋白激活化合物的沉默信息调节蛋白调节化合物及其应用 |
| US12012370B1 (en) | 2022-12-29 | 2024-06-18 | Codagen Biosciences, Inc. | Sirtuin modulating compounds and applications thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1108698B (de) | 1959-09-03 | 1961-06-15 | Hoechst Ag | Verfahren zur Herstellung von 2-(2'-Aminoaryl)-4, 5-arylen-1, 2, 3-triazolen |
| US3517007A (en) * | 1968-04-05 | 1970-06-23 | American Home Prod | 5 - acetamido - 4 - pyrimidinecarboxamides,5 - acetamido - 4 - pyrimidinecarboxylic acid hydrazides and related compounds |
| ZA735753B (en) | 1972-09-14 | 1974-07-31 | American Cyanamid Co | Resolution of 6-substituted amino phenyl-2,3,5,6-tetrahydro(2,1-b)thiadiazoles |
| US4018932A (en) * | 1975-11-03 | 1977-04-19 | American Cyanamid Company | Anthelmintic pour-on formulations for topical use on domestic and farm animals |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4939133A (en) * | 1985-10-01 | 1990-07-03 | Warner-Lambert Company | N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade |
| JPH0576084A (ja) | 1991-09-11 | 1993-03-26 | Matsushita Electric Ind Co Ltd | 遠隔表示装置 |
| JPH05289689A (ja) | 1992-04-06 | 1993-11-05 | Sanyo Electric Co Ltd | 可搬性規則音声合成装置 |
| JPH07291976A (ja) | 1994-04-27 | 1995-11-07 | Otsuka Pharmaceut Factory Inc | イミダゾ〔２，１−ｂ〕チアゾール誘導体 |
| US6653309B1 (en) * | 1999-04-26 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme technical field of the invention |
| DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
| WO2003000682A1 (en) * | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
| EA007339B1 (ru) | 2001-07-27 | 2006-08-25 | Кьюэрис, Инк. | Медиаторы путей передачи сигналов генами hedgehog, содержащие их композиции и способы применения указанных веществ |
| HUP0103986A2 (hu) | 2001-09-28 | 2003-06-28 | Richter Gedeon Vegyészeti Gyár Rt. | Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| HUP0103987A3 (en) | 2001-09-28 | 2004-11-29 | Richter Gedeon Vegyeszet | Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates |
| JP2005298333A (ja) | 2001-11-15 | 2005-10-27 | Meiji Seika Kaisha Ltd | 新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤 |
| MXPA05009245A (es) * | 2003-03-11 | 2005-10-19 | Pfizer Prod Inc | Nuevos compuestos de pirazina como inhibidores del factor de crecimiento transformante (tgf). |
| JP2006519791A (ja) | 2003-03-13 | 2006-08-31 | ノボ ノルディスク アクティーゼルスカブ | 新規なｎｐｈインスリン製剤 |
| EP1694410B1 (en) | 2003-12-15 | 2010-04-14 | Japan Tobacco, Inc. | Cyclopropane derivatives and pharmaceutical use thereof |
| WO2005069998A2 (en) | 2004-01-20 | 2005-08-04 | Brigham Young University Technology Transfer Office | Novel sirtuin activating compounds and methods for making the same |
| EP1740181A1 (en) * | 2004-04-22 | 2007-01-10 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for the treatment of sexual disorders ii |
| ES2663226T3 (es) * | 2004-06-04 | 2018-04-11 | Washington University | Procedimientos y composiciones para tratar neuropatías |
| EP1819341A4 (en) | 2004-11-10 | 2011-06-29 | Synta Pharmaceuticals Corp | IL-12 MODULATORY CONNECTIONS |
| JP2008535790A (ja) | 2005-03-03 | 2008-09-04 | サートリス ファーマシューティカルズ， インコーポレイテッド | サーチュインモジュレーターであるｎ−フェニルベンズアミド誘導体 |
| KR20080019213A (ko) | 2005-05-09 | 2008-03-03 | 아칠리온 파르마세우티칼스 인코포레이티드 | 티아졸 화합물 및 그 사용방법 |
| US8093401B2 (en) * | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| AU2006278504B2 (en) * | 2005-08-04 | 2013-01-17 | Sirtris Pharmaceuticals, Inc. | Imidazopyridine derivatives as sirtuin modulating agents |
| US8088928B2 (en) * | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US7855289B2 (en) * | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| EA019951B1 (ru) | 2007-03-01 | 2014-07-30 | Новартис Аг | Ингибиторы киназы pim и способы их применения |
| CL2008001822A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
| TW200918542A (en) | 2007-06-20 | 2009-05-01 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| EP2217606A1 (en) | 2007-11-08 | 2010-08-18 | Sirtris Pharmaceuticals, Inc. | Solubilized thiazolopyridines |
| US20100168084A1 (en) | 2008-05-08 | 2010-07-01 | Huber L Julie | Therapeutic compounds and related methods of use |
-
2008
- 2008-06-19 TW TW097122811A patent/TW200918542A/zh unknown
- 2008-06-19 CL CL2008001821A patent/CL2008001821A1/es unknown
- 2008-06-20 ES ES08768696.0T patent/ES2534544T3/es active Active
- 2008-06-20 WO PCT/US2008/007771 patent/WO2008156866A1/en not_active Ceased
- 2008-06-20 NZ NZ581989A patent/NZ581989A/en not_active IP Right Cessation
- 2008-06-20 UY UY31170A patent/UY31170A1/es not_active Application Discontinuation
- 2008-06-20 JP JP2010513266A patent/JP5281081B2/ja not_active Expired - Fee Related
- 2008-06-20 EP EP08768696.0A patent/EP2167510B1/en active Active
- 2008-06-20 PE PE2008001057A patent/PE20090423A1/es active IP Right Grant
- 2008-06-20 AR ARP080102662A patent/AR067106A1/es unknown
- 2008-06-20 MX MX2009013976A patent/MX2009013976A/es active IP Right Grant
- 2008-06-20 CN CN2008801034489A patent/CN101874031B/zh not_active Expired - Fee Related
- 2008-06-20 BR BRPI0813653-0A2A patent/BRPI0813653A2/pt not_active Application Discontinuation
- 2008-06-20 EA EA201070034A patent/EA018182B1/ru not_active IP Right Cessation
- 2008-06-20 AU AU2008266746A patent/AU2008266746B2/en not_active Ceased
- 2008-06-20 KR KR1020107000398A patent/KR101525268B1/ko not_active Expired - Fee Related
- 2008-06-20 UA UAA201000211A patent/UA104127C2/ru unknown
- 2008-06-20 US US12/214,804 patent/US7829556B2/en not_active Expired - Fee Related
- 2008-06-20 CA CA2692099A patent/CA2692099C/en not_active Expired - Fee Related
- 2008-06-20 MY MYPI20095422A patent/MY149316A/en unknown
-
2009
- 2009-12-11 DO DO2009000283A patent/DOP2009000283A/es unknown
- 2009-12-14 IL IL202729A patent/IL202729A/en not_active IP Right Cessation
- 2009-12-14 ZA ZA200908882A patent/ZA200908882B/xx unknown
-
2010
- 2010-01-08 CO CO10001888A patent/CO6261382A2/es active IP Right Grant
- 2010-01-15 MA MA32518A patent/MA31568B1/fr unknown
- 2010-01-20 CR CR11231A patent/CR11231A/es unknown
- 2010-09-27 US US12/891,667 patent/US8247565B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010530431A5 (OSRAM) | ||
| JP2010530432A5 (OSRAM) | ||
| RU2445312C2 (ru) | ПРОИЗВОДНЫЕ 2-МЕТИЛМОРФОЛИН ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR | |
| US20040209891A1 (en) | Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV | |
| RU2559888C2 (ru) | Аналоги этомидата, которые не ингибируют синтез адренокортикостероидов | |
| AU2002244860A1 (en) | Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV | |
| JP2011502958A5 (OSRAM) | ||
| JP2011500545A5 (OSRAM) | ||
| JP2004528334A5 (OSRAM) | ||
| WO2005075425A3 (en) | Substituted bisarylurea derivatives as kinase inhibitors | |
| UY28496A1 (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4 | |
| JP2005002129A5 (OSRAM) | ||
| JP2005526696A5 (OSRAM) | ||
| JP2008503533A5 (OSRAM) | ||
| MA28706B1 (fr) | Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques | |
| JP2007530493A5 (OSRAM) | ||
| JP2012515788A5 (OSRAM) | ||
| JP2013518036A5 (OSRAM) | ||
| TW200924745A (en) | Organic compounds | |
| JP2009541387A5 (OSRAM) | ||
| WO2006085113A3 (en) | 2-substituted 5-membered heteroaryl carboxylates as hm74a receptor agonists | |
| NO20034007D0 (no) | N-fenylarylsulfonamidforbindelse, legemiddel inneholdende forbindelsen somaktiv bestanddel, mellomprodukt for forbindelsen, ogfremgangsmåter for fremstilling av samme | |
| NO20064811L (no) | 4-(5-aminometyl-2-fluor-fenyl)-piperidin-1-yl]-(4-brom-3-metyl-5-propoksy-tiofen-2-yl)-metanonhydroklorid som en inhibitor av mastcelletryptase | |
| RU2003131970A (ru) | Производные 4-(фенил-пиперидин-4-илиден-метил)-бензамида и их применение для лечения боли, тревоги или желудочно-кишечных расстройств | |
| RU2008110644A (ru) | Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств |